Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.33 -1.1%	$1.34	$0.77 ▼ $2.63	$109.96M	1.05	350,501 shs	1.66 million shs
CYTH Cyclo Therapeutics	$0.72	$0.72	$0.55 ▼ $1.45	$23.72M	-0.57	585,177 shs	N/A
IVVD Invivyd	$0.71 -11.4%	$0.77	$0.35 ▼ $2.74	$84.93M	0.51	7.01 million shs	983,642 shs
TCRX TScan Therapeutics	$1.80 -0.6%	$1.67	$1.02 ▼ $6.23	$101.86M	0.99	470,300 shs	95,203 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	+20.18%	+24.07%	+3.88%	+20.72%	-32.66%
CYTH Cyclo Therapeutics	0.00%	0.00%	0.00%	0.00%	-39.45%
IVVD Invivyd	+0.79%	+6.57%	+17.11%	+2.91%	-18.44%
TCRX TScan Therapeutics	+2.26%	+9.70%	+2.26%	+45.97%	-67.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDL Cardiol Therapeutics	2.5408 of 5 stars	3.7	2.0	0.0	0.0	3.8	0.0	0.6
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	4.0124 of 5 stars	3.6	5.0	0.0	0.0	3.7	3.3	0.6
TCRX TScan Therapeutics	3.6779 of 5 stars	3.5	5.0	0.0	0.0	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	503.77% Upside
CYTH Cyclo Therapeutics	2.33	Hold	$0.95	31.83% Upside
IVVD Invivyd	3.25	Buy	$3.85	443.79% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	333.33% Upside

Current Analyst Ratings Breakdown

Latest CYTH, TCRX, IVVD, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $3.00
8/12/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/16/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
CYTH Cyclo Therapeutics	$870.73K	27.24	N/A	N/A	$0.21 per share	3.43
IVVD Invivyd	$25.38M	3.35	N/A	N/A	$0.56 per share	1.26
TCRX TScan Therapeutics	$2.82M	36.12	N/A	N/A	$3.12 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	N/A
CYTH Cyclo Therapeutics	-$20.06M	-$0.90	N/A	N/A	N/A	-2,847.19%	N/A	-307.16%	N/A
IVVD Invivyd	-$169.93M	-$1.20	N/A	6.44	N/A	-389.01%	-165.24%	-99.71%	N/A
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-1,964.88%	-63.33%	-40.19%	N/A

Latest CYTH, TCRX, IVVD, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	-$0.07	+$0.04	-$0.07	N/A	N/A
8/14/2025	Q2 2025	IVVD Invivyd	-$0.04	-$0.12	-$0.08	-$0.12	$23.16 million	$11.79 million
8/12/2025	Q2 2025	TCRX TScan Therapeutics	-$0.28	-$0.2848	-$0.0048	-$0.28	$1.31 million	$3.08 million
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	0.01	3.26	3.26
CYTH Cyclo Therapeutics	N/A	0.17	0.16
IVVD Invivyd	N/A	1.53	1.53
TCRX TScan Therapeutics	0.18	7.06	8.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
CYTH Cyclo Therapeutics	68.55%
IVVD Invivyd	70.36%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
CYTH Cyclo Therapeutics	29.78%
IVVD Invivyd	25.40%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	82.68 million	78.34 million	Not Optionable
CYTH Cyclo Therapeutics	9	32.92 million	23.12 million	No Data
IVVD Invivyd	100	119.96 million	89.49 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	54.13 million	Not Optionable

CYTH, TCRX, IVVD, and CRDL Headlines

Recent News About These Companies

Wedbush Reaffirms Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

August 14 at 2:15 AM | americanbankingnews.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

August 13 at 1:41 PM | marketbeat.com

TScan Therapeutics Reports Q2 2025 Financial Results

August 13 at 8:28 AM | msn.com

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

August 12 at 5:26 PM | msn.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

August 12 at 4:01 PM | zacks.com

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12 at 7:00 AM | globenewswire.com

TScan Therapeutics (TCRX) to Release Quarterly Earnings on Monday

August 10, 2025 | americanbankingnews.com

Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) Price Target at $7.80

August 6, 2025 | americanbankingnews.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

August 5, 2025 | marketbeat.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by Brokerages

August 3, 2025 | marketbeat.com

TScan Therapeutics Elects New Directors at Annual Meeting

July 27, 2025 | theglobeandmail.com

One TScan Therapeutics Insider Raised Stake By 18% In Previous Year

July 19, 2025 | finance.yahoo.com

Tscan Therapeutics Inc News (TCRX) - Investing.com

July 9, 2025 | investing.com

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

What Analysts Are Saying About TScan Therapeutics Stock

May 9, 2025 | nasdaq.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTH, TCRX, IVVD, and CRDL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$1.32 -0.02 (-1.12%)

As of 02:47 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cyclo Therapeutics NASDAQ:CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Invivyd NASDAQ:IVVD

$0.71 -0.09 (-11.42%)

As of 02:47 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics NASDAQ:TCRX

$1.80 -0.01 (-0.55%)

As of 02:47 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time